ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "285: CRISPR history, biotech struggles, & a big week for deals"
Episode Synopsis
With the first CRISPR-based medicine expected to win FDA approval any minute now, STAT’s Megan Molteni joins us to discuss how we got here and what it means for the future. Then, Bruce Booth from Atlas Venture joins us to discuss what was yet another downbeat year for biotech and whether there’s reason for optimism heading into 2024.
To keep up with biotech news throughout the week, here's where you can subscribe to our newsletter, The Readout.
To keep up with biotech news throughout the week, here's where you can subscribe to our newsletter, The Readout.
More episodes of the podcast The Readout Loud
382: Biotech's year in review
18/12/2025
In God we trust